Last reviewed · How we verify
NCT05674981
To Evaluate the Beneficial Effect of Probiotics on DKD Patients and the Role of Gut Microbiota Modulation
NA trial testing Probiotic group in Diabetic Kidney Disease in 50 participants. Completed in 8 May 2025.
24 April 2025
Quick facts
| Lead sponsor | GenMont Biotech Incorporation |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 50 |
| Start date | 24 April 2023 |
| Primary completion | 24 April 2025 |
| Estimated completion | 8 May 2025 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Probiotic group
- Placebo group
Conditions studied
- Diabetic Kidney Disease — all drugs for Diabetic Kidney Disease →
Sponsor
GenMont Biotech Incorporation — full company profile →
Who can join
Adults 25 to 80, any sex, with Diabetic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the efficacy of probiotics in the treatment of diabetic kidney disease, this study is designed to explore after consumption of probiotics lactobacillus reuteri ADR-1 and lactobacillus rhamnosus GM-020 composite strain powder sachets for 6 months, whether the improvement of blood sugar, kidney related indicators can further improve the course of diabetic kidney disease. The clinical trial predicted that probiotics can improve diabetic kidney disease by changing the intestinal flora by inhibiting harmful bacteria, reduction of systemic oxidative stress, balance carbohydrate and fat metabolism, further preventing the progress of diabetic kidney disease.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Synbiotics, prebiotics and probiotics for people with chronic kidney disease.
Cooper TE, Khalid R, Chan S, Craig JC, et al · · 2023 · cited 35× · PMID 37870148 · DOI 10.1002/14651858.cd013631.pub2
Verify or expand the search:
- PubMed search for NCT05674981
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Probiotic group
Trials testing the same drug.
- NCT07165457 — Effect of Probiotic Intake in Healthy Population · NA · not yet recruiting
- NCT07081100 — Probiotics and Non-Organic Gastrointestinal Improvement · NA · recruiting
- NCT06873438 — The Effect of Probiotics on the Improvement of Intestinal and Immune Function · NA · completed
- NCT06899620 — BC179 Relieves Discomfort After Drinking · NA · completed
- NCT06629441 — Effectiveness and Safety of Probiotics in Relieving Anxiety and Depression · NA · completed
Other recruiting trials for Diabetic Kidney Disease
Currently open trials in the same condition.
- NCT07169422 — Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care · NA · recruiting
- NCT06666283 — A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients · Phase 1 · recruiting
- NCT07338435 — "Residual Kidney Function and Oxidative Stress in Incremental vs Standard Peritoneal Dialysis (2 Mexican Centers)" · NA · active not recruiting
- NCT06441591 — Clinical Outcome of Vinpocetine in Diabetic Nephropathy · Phase 2, PHASE3 · recruiting
- NCT06532682 — Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes · Phase 4 · active not recruiting
Other GenMont Biotech Incorporation trials
Trials by the same sponsor.
- NCT06039644 — To Evaluate the Clinical Efficacy of Probiotics in Patients With the Breast Cancer · NA · recruiting
- NCT05402449 — To Evaluate the Beneficial Effect of Probiotics on NAFLD Patients and the Role of Gut Microbiota Modulation · NA · completed
- NCT04566549 — The Safety and Efficacy Evaluation of Hair Products Containing Probiotics · Phase 2 · completed
- NCT04190485 — To Evaluate the Efficacy of Probiotics Toothpastes in Improvement of Gingivitis and Prevention of Periodontal Diseases V · NA · completed
- NCT04094129 — Evaluation of the Effect of Wismemo on Alzheimer's Dementia Patients · NA · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05674981 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GenMont Biotech Incorporation
- Last refreshed: 8 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05674981.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing